Form 8-K - Current report:
SEC Accession No. 0001104659-25-052452
Filing Date
2025-05-23
Accepted
2025-05-23 16:22:38
Documents
16
Period of Report
2025-05-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2516054d1_8k.htm   iXBRL 8-K 31274
2 EXHIBIT 1.1 tm2516054d1_ex1-1.htm EX-1.1 247833
3 EXHIBIT 4.1 tm2516054d1_ex4-1.htm EX-4.1 105705
4 EXHIBIT 5.1 tm2516054d1_ex5-1.htm EX-5.1 16147
8 GRAPHIC tm2516054d1_ex5-1img001.jpg GRAPHIC 3105
  Complete submission text file 0001104659-25-052452.txt   664421

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA otlk-20250522.xsd EX-101.SCH 3047
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20250522_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20250522_pre.xml EX-101.PRE 22380
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2516054d1_8k_htm.xml XML 3656
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 25982616
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)